Laboratory Corporation of America Holdings
- Industria
- Diagnostics
- Bolsa
- EE. UU.
- País / Región
- USA
- Fecha de salida a bolsa
- 29 de marzo de 1990
- Empleados
- 71.000
- Sitio web
- www.labcorp.com
Rango de valoración compuesto · conservador $145–$200 / razonable $220–$280 / optimista $280–$326. A $301.17, Dentro del rango de valor intrínseco optimista · con muchas expectativas ya descontadas.
Al publicar $262.75 (29 de mayo de 2026)
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Historia
Laboratory Corporation of America Holdings (Labcorp) was founded in 1995 and is headquartered in Burlington, North Carolina; its IPO date was March 29, 1990. The company operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. A defining structural change came in 2023, when Labcorp spun off its former clinical development and commercialization business, Fortrea, leaving Diagnostics Laboratories and Biopharma Laboratory Services as the core. From the spin-off Labcorp received a cash distribution of approximately $1.6 billion, which it primarily directed toward roughly $1 billion of share repurchases and $300 million of debt repayment. The company subsequently expanded through acquisitions concentrated in specialty testing and regional network growth, including the 2024 acquisitions of Invitae, BioReference Health, and several health-system outreach laboratory businesses. By 2025, total revenue reached $13.95 billion, with Diagnostics Laboratories contributing $10.88 billion (about 78%) and Biopharma Laboratory Services contributing $3.10 billion (about 22%); the company employed about 71,000 people and operated in roughly 100 countries.
Posición en el sector
Labcorp is one of two scaled national diagnostics platforms in the United States, with Quest Diagnostics as its closest comparable competitor in the Diagnostics business; Quest reported 2025 revenue of $11.04 billion, comparable in size to Labcorp's Diagnostics segment. In Biopharma Laboratory Services, Labcorp's position is closer to IQVIA's Research & Development Solutions, which generated $8.896 billion of revenue in 2025 against IQVIA total revenue of $16.31 billion. Labcorp estimates the U.S. clinical laboratory market at over $80 billion, while global biopharmaceutical R&D spending served by its Biopharma segment exceeded $200 billion in 2025. The company's scale advantage rests on an industrialized national-to-international network that is difficult to replicate: more than 2,200 patient service centers and over 7,000 in-field phlebotomists in the United States, more than 90,000 electronic interfaces, results typically returned within 1 to 2 days, and coverage placing most U.S. households within 10 miles of a Labcorp location; the company processes about 750 million tests per year. Regulatory and quality barriers reinforce this position: in 2025, 25 regional and specialty laboratories held ISO 15189 accreditation, 5 laboratories held ISO 13485, and 2 laboratories held both.
Aún no hay análisis sobre este valor en tu idioma.